Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine in healthy Chinese girls and women aged 9 to 45 years: results from 2 randomized controlled …
F Zhu, J Li, Y Hu, X Zhang, X Yang, H Zhao… - Human Vaccines & …, 2014 - Taylor & Francis
Immunogenicity and safety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted
vaccine were evaluated in healthy Chinese females aged 9–45 years in 2 phase IIIB …
vaccine were evaluated in healthy Chinese females aged 9–45 years in 2 phase IIIB …
Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2 …
This observer-blind study (clinicaltrials. gov NCT01462357) compared the immunogenicity
and safety of 2 doses of the HPV-16/18 AS04-adjuvanted vaccine (HPV-16/18 (2D)) vs. 2 or …
and safety of 2 doses of the HPV-16/18 AS04-adjuvanted vaccine (HPV-16/18 (2D)) vs. 2 or …
Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared with the …
S Esposito, V Birlutiu, P Jarcuska… - The Pediatric …, 2011 - journals.lww.com
Background: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is
immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent …
immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent …
Efficacy of the AS04-adjuvanted HPV-16/18 vaccine in young Chinese women with oncogenic HPV infection at baseline: post-hoc analysis of a randomized controlled …
S Hu, X Xu, F Zhu, Y Hong, Y Hu, X Zhang… - Human Vaccines & …, 2021 - Taylor & Francis
Human papillomavirus (HPV) vaccines are efficacious against HPV infections and
associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) …
associated lesions in women HPV-naïve at vaccination. However, vaccine efficacy (VE) …
Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: Results from a …
B Romanowski, TF Schwarz, LM Ferguson… - Human …, 2011 - Taylor & Francis
The immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine
(Cervarix®, GlaxoSmithKline Biologicals) administered according to its licensed vaccination …
(Cervarix®, GlaxoSmithKline Biologicals) administered according to its licensed vaccination …
Four-year follow-up of the immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine when administered to adolescent girls aged 10–14 years
TF Schwarz, LM Huang, DMR Medina… - Journal of Adolescent …, 2012 - Elsevier
PURPOSE: Long-term immunogenicity and safety of the human papillomavirus (HPV)-16/18
AS04-adjuvanted vaccine when administered to adolescent girls was evaluated. METHODS …
AS04-adjuvanted vaccine when administered to adolescent girls was evaluated. METHODS …
Efficacy, immunogenicity and safety of the HPV‐16/18 AS04‐adjuvanted vaccine in healthy Chinese women aged 18–25 years: results from a randomized controlled …
FC Zhu, W Chen, YM Hu, Y Hong, J Li… - … Journal of Cancer, 2014 - Wiley Online Library
This phase II/III, double‐blind, randomized trial assessed the efficacy, immunogenicity and
safety of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in young …
safety of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in young …
Safety and immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine: a randomized, controlled trial in adolescent girls
DMR Medina, A Valencia, A de Velasquez… - Journal of Adolescent …, 2010 - Elsevier
PURPOSE: Immunization of girls against oncogenic human papillomavirus (HPV) types
before sexual debut is important for cervical cancer prevention. This phase III blinded …
before sexual debut is important for cervical cancer prevention. This phase III blinded …
Safety and Immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine in 4–6-year-old girls: results to month 12 from a randomized trial
L Lin, MM Parra, VY Sierra, AS Cespedes… - The Pediatric …, 2018 - journals.lww.com
Background: The burden of cervical cancer caused by human papillomavirus (HPV) is high
in Latin America. The suboptimal HPV vaccination coverage in adolescents could be …
in Latin America. The suboptimal HPV vaccination coverage in adolescents could be …
Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
LW Shi, J Li, BW Yu, LR Huang, K Li, M Ji… - Human Vaccines & …, 2023 - Taylor & Francis
As global supply is still inadequate to address the worldwide requirements for HPV
vaccines, we assessed the safety and immunogenicity of a new bivalent HPV16/18 vaccine …
vaccines, we assessed the safety and immunogenicity of a new bivalent HPV16/18 vaccine …